Determine the necessary mass, volume, or concentration for preparing a solution.
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
SKU | Size | Availability | Price | Qty |
---|---|---|---|---|
T287081-1mg | 1mg | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $99.90 | |
T287081-5mg | 5mg | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $299.90 | |
T287081-10mg | 10mg | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $399.90 | |
T287081-25mg | 25mg | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $699.90 | |
T287081-50mg | 50mg | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $999.90 | |
T287081-100mg | 100mg | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $1,599.90 |
Potent hematopoietic prostaglandin D synthase (H-PGDS) inhibitor
Synonyms | N-[4-[4-(4-Morpholinylcarbonyl)-1-piperidinyl]phenyl]-2-phenoxy-5-pyrimidinecarboxamide |
---|---|
Specifications & Purity | Moligand™, ≥98%(HPLC) |
Biochemical and Physiological Mechanisms | Potent hematopoietic prostaglandin D synthase (H-PGDS) inhibitor (IC50= 83 nM). Inhibits PGD2production and late phase nasal blockage in an animal model of allergic rhinitis. Exhibits negligible effects on COX-1, COX-2, 5-LOX, LTC4synthase, TXA2synthase a |
Storage Temp | Store at -20°C |
Shipped In | Ice chest + Ice pads |
Grade | Moligand™ |
Action Type | INHIBITOR |
Mechanism of action | Inhibitor of H-PGDS |
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
IUPAC Name | N-[4-[4-(morpholine-4-carbonyl)piperidin-1-yl]phenyl]-2-phenoxypyrimidine-5-carboxamide |
---|---|
INCHI | InChI=1S/C27H29N5O4/c33-25(21-18-28-27(29-19-21)36-24-4-2-1-3-5-24)30-22-6-8-23(9-7-22)31-12-10-20(11-13-31)26(34)32-14-16-35-17-15-32/h1-9,18-20H,10-17H2,(H,30,33) |
InChi Key | NLSSUSRERAMBTA-UHFFFAOYSA-N |
Canonical SMILES | C1CN(CCC1C(=O)N2CCOCC2)C3=CC=C(C=C3)NC(=O)C4=CN=C(N=C4)OC5=CC=CC=C5 |
Isomeric SMILES | C1CN(CCC1C(=O)N2CCOCC2)C3=CC=C(C=C3)NC(=O)C4=CN=C(N=C4)OC5=CC=CC=C5 |
PubChem CID | 16040067 |
Molecular Weight | 487.55 |
PubChem CID | 16040067 |
---|---|
BindingDB Ligand | 50463722 |
ChEMBL Ligand | CHEMBL4238186 |
CAS Registry No. | 927878-49-7 |
Enter Lot Number to search for COA:
To view the certificate results,please click on a Lot number.For Lot numbers from past orders,please use our order status section
Lot Number | Certificate Type | Date | Item |
---|---|---|---|
E2431367 | Certificate of Analysis | Feb 26, 2024 | T287081 |
E2431380 | Certificate of Analysis | Feb 26, 2024 | T287081 |
E2431472 | Certificate of Analysis | Feb 26, 2024 | T287081 |
E2431473 | Certificate of Analysis | Feb 26, 2024 | T287081 |
E2431474 | Certificate of Analysis | Feb 26, 2024 | T287081 |
E2431475 | Certificate of Analysis | Feb 26, 2024 | T287081 |
E2431476 | Certificate of Analysis | Feb 26, 2024 | T287081 |
E2431477 | Certificate of Analysis | Feb 26, 2024 | T287081 |
E2431478 | Certificate of Analysis | Feb 26, 2024 | T287081 |
E2431479 | Certificate of Analysis | Feb 26, 2024 | T287081 |
E2431480 | Certificate of Analysis | Feb 26, 2024 | T287081 |
E2431481 | Certificate of Analysis | Feb 26, 2024 | T287081 |
Solubility | Solvent:DMSO, Max Conc. mg/mL: 48.76, Max Conc. mM: 100 |
---|
1. Takaya D, Inaka K, Omura A, Takenuki K, Kawanishi M, Yabuki Y, Nakagawa Y, Tsuganezawa K, Ogawa N, Watanabe C et al.. (2018) Characterization of crystal water molecules in a high-affinity inhibitor and hematopoietic prostaglandin D synthase complex by interaction energy studies.. Bioorg Med Chem, 26 (16): (4726-4734). [PMID:30121213] |